國藥集團中國生物復諾健mRNA疫苗產業化基地正式開工
國藥集團中國生物復諾健mRNA疫苗產業化基地開工儀式日前在上海舉行。該基地總建築面積超過3.25萬平方米,生產車間將超過1.6萬平方米,竣工投產後將成為國內設計產能、技術方面領先的mRNA疫苗生產車間。
中國生物復諾健mRNA變異株新冠疫苗,在9月2日召開的中國國際服務貿易博覽會上首次亮相,該疫苗擁有自主知識產權。此次mRNA疫苗產業化項目啟動,將為加快mRNA疫苗的研發和產業化進程提供先決條件。(ta/k)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.